Article placeholder black
Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease
Article placeholder black
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2023
Article placeholder black
Neuroimmune Interactions: From Basic Mechanisms to Novel Therapeutic Directions
Article placeholder black
Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting
Article placeholder black
epocrates and Cognito Therapeutics Join Forces to Deliver Video Messaging to Healthcare Professionals
Article placeholder black
Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances
Article placeholder black
Cognito finds new medical, technology heads in BrainStorm, Philips alums
Article placeholder black
Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer’s Disease at AD/PD 2023
Article placeholder black
Neuro Startup Cognito Corrals $73M as Alzheimer’s Device Commences Key Test
Article placeholder black
Can light reset brainwaves to treat Alzheimer’s? This Boston startup has $73 million to find out.
Article placeholder black
Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's
Designimage
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease
Article placeholder black
Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
6310be6b3fe7c40019e4d532
The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
Designimage
Startup’s Headset to Treat Alzheimer’s Will Undergo Wide Trial With Patients
Article placeholder black
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference
Fierceimage
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
Article placeholder black
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
Article placeholder black
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022
article placeholder
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
Economist77
Some health apps are able not just to diagnose diseases, but also to treat them
Article placeholder black
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
Statimage
With pharma still struggling in Alzheimer’s, health tech companies want a swing
article placeholder
Ushering in a New Class of Disease-Modifying DTx
Healio media
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients
article placeholder
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
article placeholder
Fierce Medtech Names Cognito Therapeutics as One of Its “Fierce 15” Med Tech Companies of 2021
Fierce 15
Fierce Medtech's 2021 Fierce 15
article placeholder
Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference
article placeholder
Cognito Therapeutics to Present Virtual Symposium “Predicting Alzheimer’s Disease Progression with Neurophysiological Markers” at 2022 AD/PD Conference
article placeholder
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
article placeholder
Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance
article placeholder
Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors
article placeholder
Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021
article placeholder
Cognito Therapeutics Announces Formation of Payor Advisory Board
article placeholder
Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021
article placeholder
Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021
article placeholder
Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021
article placeholder
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
article placeholder
Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease
article placeholder
Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer
article placeholder
Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer
article placeholder
Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021
article placeholder
Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease
article placeholder
Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference
article placeholder
Cognito Therapeutics Appoints Mark Day, Ph.D., as Chief Business Officer
article placeholder
Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease
article placeholder
Cognito Therapeutics Appoints Industry Pioneer Brent Vaughan as Chief Executive Officer